We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Medexus Pharmaceuticals Inc (MDP) NPV

Sell:2.12 CAD Buy:2.14 CAD Change: 0.02 CAD (0.93%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:2.12 CAD
Buy:2.14 CAD
Change: 0.02 CAD (0.93%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:2.12 CAD
Buy:2.14 CAD
Change: 0.02 CAD (0.93%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Contact details

Address:
10 King Street East, Suite 600
TORONTO
M5C 1C3
Canada
Telephone:
+1 (514) 7622626
Website:
https://www.medexus.com/en_US

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MDP
ISIN:
CA58410Q2036
Market cap:
53.08 million CAD
Shares in issue:
24.65 million
Sector:
Pharmaceuticals
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Ken D'entremont
    Chief Executive Officer, Director
  • Brendon Buschman
    Chief Financial Officer
  • Ian Wildgoose Brown
    General Counsel, Corporate Secretary
  • Richard Labelle
    General Manager, Canadian Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.